Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer

BJU International

Volumn 109, Issue 4, 2012, Pages 520-524

  Røder, Martin Andreas ^a   Christensen, Ib Jarle ^b   Berg, Kasper D ^a   Gruschy, Lisa ^a   Brasso, Klaus ^a   Iversen, Peter ^a  

^a Department of Urology ^*  (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

biochemical failure; localized prostate cancer; prediction; testosterone

Indexed keywords

GOSERELIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RISK ASSESSMENT; RISK REDUCTION; TESTOSTERONE BLOOD LEVEL;

AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 84857033892     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10335.x     Document Type: Article

References (28)

1. Morote J, Ramirez C, Gomez E, et al,. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int 2009; 104: 486-9
2. Sawada N, Iwasaki M, Inoue M, et al,. Plasma testosterone and sex hormone-binding globulin concentrations and the risk of prostate cancer among Japanese men: a nested case-control study. Cancer Sci 2010; 101: 2652-7
3. Nomura A, Heilbrun LK, Stemmermann GN, Judd HL,. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988; 48: 3515-7
4. Campbell MF, Wein AJ, Kavoussi LR,. Campbell-Walsh Urology, 9th edn., Wein AJ, Kavoussi LR, Novick AL, Partin AW, Peters CA, eds, Philadelphia: WB Saunders, 2007
5. Xylinas E, Ploussard G, Durand X, et al,. Low pretreatment total testosterone (<3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU Int 2011; 107: 1400-3
6. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM,. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005; 174: 2178-80 (Pubitemid 41611769)
7. Yamamoto S, Yonese J, Kawakami S, et al,. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007; 52: 696-701 (Pubitemid 47126163)
8. Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA,. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008; 72: 1240-5
9. Rose RM, Kreuz LE, Holaday JW, Sulak KJ, Johnson CE,. Diurnal variation of plasma testosterone and cortisol. J Endocrinol 1972; 54: 177-8
10. Piro C, Fraioli F, Sciarra F, Conti C,. Circadian rhythm of plasma testosterone, cortisol and gonadotropins in normal male subjects. J Steroid Biochem 1973; 4: 321-9
11. Roddam AW, Allen NE, Appleby P, Key TJ,. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-83 (Pubitemid 351480553)
12. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA,. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005; 173: 1935-7 (Pubitemid 40675215)
13. Massengill JC, Sun L, Moul JW, et al,. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670-5 (Pubitemid 36443468)
14. Miller LR, Partin AW, Chan DW, et al,. Influence of radical prostatectomy on serum hormone levels. J Urol 1998; 160: 449-53 (Pubitemid 29476696)
15. Risbridger GP,. Recent progress in our understanding of inhibin in the prostate gland. J Endocrinol 1998; 157: 1-4
16. Imamoto T, Suzuki H, Yano M, et al,. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients? Prostate Cancer Prostatic Dis 2009; 12: 78-82
17. Lukkarinen O,. Total and SHBG-bound testosterone and 5 alpha-dihydrotestosterone serum concentrations in normal elderly men and patients with benign prostatic hypertrophy before and after removal of the adenoma. Br J Urol 1980; 52: 377-80 (Pubitemid 10010928)
18. Schatzl G, Madersbacher S, Haitel A, et al,. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312-5 (Pubitemid 36323774)
19. Schatzl G, Madersbacher S, Thurridl T, et al,. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001; 47: 52-8 (Pubitemid 32246752)
20. Schatzl G, Brossner C, Schmid S, et al,. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000; 55: 397-402 (Pubitemid 30110593)
21. Hoffman MA, DeWolf WC, Morgentaler A,. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824-7 (Pubitemid 30091624)
22. Bhasin S, Cunningham GR, Hayes FJ, et al,. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010 (Pubitemid 43854972)
23. Gray A, Feldman HA, McKinlay JB, Longcope C,. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016-25 (Pubitemid 21901140)
24. Stephenson AJ, Scardino PT, Eastham JA, et al,. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98: 715-7 (Pubitemid 43821789)
25. Cooperberg MR, Freedland SJ, Pasta DJ, et al,. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006; 107: 2384-91 (Pubitemid 44748521)
26. Van Poppel H, De Ridder D, Elgamal AA, et al,. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 1995; 154: 429-34
27. Bullock MJ, Srigley JR, Klotz LH, Goldenberg SL,. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 2002; 26: 1400-13 (Pubitemid 35239416)
28. Aus G, Abrahamsson PA, Ahlgren G, et al,. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002; 90: 561-6